While the median age of patients diagnosed with melanoma is between 45 to 55, retirement living seniors are at risk as well. A new breakthrough may help those with skin cancer and even save lives.
Researchers at the University of Nottingham's Division of Clinical Oncology have been given the greenlight to test out a vaccine that may cure the skin disease.
The hope is that the treatment will be able to do what normal modern methods have not.
"In cases where it has not been picked up until further down the line, we have found that chemotherapy and radiotherapy simply do not work," said Professor Lindy Durrant.
According to MelanomaCenter.org, the incident rate of the disease has more than doubled since 1973. Still, Durrant remains optimistic that the vaccine will change lives.
"It is still at a very early stage and impossible to predict the outcome of the clinical trial, but if our results from the lab are replicated in patients I think we have a good chance of dramatically improving the chances of successful treatment," she said.